DRG Epidemiology's coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
DRG Epidemiology's coverage of cervical cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key cervical cancer patient populations covering 171 countries…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pancreatic cancer patient populations, covering 171 countries and…
The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval of hormonal agents such as Zytiga (Johnson & Johnson), Xtandi (…
The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-…
The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-…
Cancer pain is a complex form of chronic pain to treat because it typically involves mixed nociceptive and neuropathic pain resulting from multiple causes (e.g., chemotherapy, metastases)…
DRG Epidemiology's coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of…
Acute myeloid leukemia (AML) is the most common form of adult leukemia but has the lowest five-year overall survival rates of all blood cancers. Historically, AML treatment in China has been…
The current treatment algorithm for non-small-cell lung cancer (NSCLC) is rapidly evolving. The increasing number of biomarker-driven therapies has resulted in a highly segmented space dominated by…
Hepatocellular carcinoma, the most common type of primary liver cancer, occurs as a results of chronic liver cirrhosis and has a five-year survival rate of only 18%. First-line advanced…